Journal: BMC Musculoskeletal Disorders

Article Title: Interleukin-6 upregulates extracellular matrix gene expression and transforming growth factor β1 activity of tendon progenitor cells

doi: 10.1186/s12891-023-07047-9

Figure Lengend Snippet: (A) TGFβ1 mRNA and (B) ELISA quantification of TGFβ1 concentration measured in TPC monolayer culture and culture media, respectively, (mean ± SD) after 72 h of culture with 0, 1, 5 and 10 ng/mL IL-6. TGFβ1 mRNA and concentration were also measured in TPC in basal medium and 10 ng/mL IL-6 supplemented with 2 μm TGFβ type I receptor (ALK-4, − 5, −7) inhibitor SB431542. Bars and errors represent mean ± SD of TGFβ1 mRNA and concentration (pg/mL)

Article Snippet: Additionally, TPC were also cultured with 0 or 2 μm TGFβ type I receptor (ALK-4, − 5, −7) inhibitor, SB431542 (Selleckchem; 13), in the presence of 0 and 10 ng/mL IL-6 for 3 days.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: BMC Musculoskeletal Disorders

Article Title: Interleukin-6 upregulates extracellular matrix gene expression and transforming growth factor β1 activity of tendon progenitor cells

doi: 10.1186/s12891-023-07047-9

Figure Lengend Snippet: (A) Tendon ECM and (B) Chondrogenic gene expression of TPC monolayers cultured in basal medium with 10 ng/mL IL-6, basal medium with 2 μm TGFβ type I receptor (ALK-4, − 5, −7) inhibitor SB431542, and 10 ng/mL IL-6 + SB431542 for 72 h. Data represents mean ± SD of fold change (normalized to housekeeping gene, EF1α) from respective values obtained from TPC monolayer cultures in basal medium alone (represented via dotted line in all graphs)

Article Snippet: Additionally, TPC were also cultured with 0 or 2 μm TGFβ type I receptor (ALK-4, − 5, −7) inhibitor, SB431542 (Selleckchem; 13), in the presence of 0 and 10 ng/mL IL-6 for 3 days.

Techniques: Gene Expression, Cell Culture

Journal: Journal of Cell Communication and Signaling

Article Title: Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes

doi: 10.1007/s12079-009-0083-1

Figure Lengend Snippet: Effects of TGF-β and TrkA signalling on CTGF gene expression in H9c2 cells. Cells were pre-treated with anti-TGF-β neutralizing antibody at 5 μg/ml (TGF-β Ab), Alk-5 inhibitor (SB431542) at 5 μM , or TrkA blocker (k252a) at 100 nM and 200 nM alone in some wells for 1 h followed by addition of unconditioned media alone or CTGF 500 ng/ml in serum free media with 0.1% BSA for 24 h. CTGF mRNA levels were measured by qRT-PCR and are shown compared with control at 100%. A, CTGF mRNA measurement by treatment with CTGF, anti-TGF-β Ab or combinations of CTGF with anti-TGF-β Ab. B, Alk 5 inhibitor. C, k252a effects on CTGF gene expression. Data shown as mean±SD. * P < 0.05 vs respective control. # P < 0.05, ## P < 0.01, ### P < 0.001 vs CTGF treatment

Article Snippet: Pan anti-TGF-β neutralizing antibody was purchased from R&D systems Inc (Minneapolis, USA) and Alk 5 inhibitor (SB 431542) was purchased from Tocris Cookson Inc, Ellisville, Missouri USA.

Techniques: Expressing, Quantitative RT-PCR, Control

Journal: Journal of Cell Communication and Signaling

Article Title: Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes

doi: 10.1007/s12079-009-0083-1

Figure Lengend Snippet: Effects of TGF-β type I receptor (Alk-5) blocker on CTGF regulated fibrotic and inflammatory gene expression in H9c2 cardiomyocytes

Article Snippet: Pan anti-TGF-β neutralizing antibody was purchased from R&D systems Inc (Minneapolis, USA) and Alk 5 inhibitor (SB 431542) was purchased from Tocris Cookson Inc, Ellisville, Missouri USA.

Techniques: Expressing